25 XP   0   0   10

Cellectis SA
Buy, Hold or Sell?

Let's analyse Cellectis together

PenkeI guess you are interested in Cellectis SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Cellectis SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Cellectis SA

I send you an email if I find something interesting about Cellectis SA.

Quick analysis of Cellectis (30 sec.)










What can you expect buying and holding a share of Cellectis? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
13.5%

What is your share worth?

Current worth
$1.06
Expected worth in 1 year
$0.09
How sure are you?
29.7%

+ What do you gain per year?

Total Gains per Share
$-0.97
Return On Investment
-36.3%

For what price can you sell your share?

Current Price per Share
$2.67
Expected price per share
$1.75 - $3.13
How sure are you?
50%

1. Valuation of Cellectis (5 min.)




Live pricePrice per Share (EOD)

$2.67

Intrinsic Value Per Share

$-2.07 - $-1.82

Total Value Per Share

$-1.01 - $-0.76

2. Growth of Cellectis (5 min.)




Is Cellectis growing?

Current yearPrevious yearGrowGrow %
How rich?$76.1m$191.4m-$86.6m-82.7%

How much money is Cellectis making?

Current yearPrevious yearGrowGrow %
Making money-$20.9m-$29m$8m38.4%
Net Profit Margin-9,764.3%-3,738.6%--

How much money comes from the company's main activities?

3. Financial Health of Cellectis (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#428 / 1031

Most Revenue
#370 / 1031

Most Profit
#738 / 1031

Most Efficient
#955 / 1031

What can you expect buying and holding a share of Cellectis? (5 min.)

Welcome investor! Cellectis's management wants to use your money to grow the business. In return you get a share of Cellectis.

What can you expect buying and holding a share of Cellectis?

First you should know what it really means to hold a share of Cellectis. And how you can make/lose money.

Speculation

The Price per Share of Cellectis is $2.67. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Cellectis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Cellectis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.06. Based on the TTM, the Book Value Change Per Share is $-0.24 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.41 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Cellectis.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.24-9.1%-0.23-8.6%-0.36-13.6%-0.33-12.2%-0.30-11.2%
Usd Book Value Change Per Share-0.28-10.7%-0.24-9.1%-0.41-15.2%-0.28-10.3%0.00-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.176.3%0.093.4%
Usd Total Gains Per Share-0.28-10.7%-0.24-9.1%-0.40-15.1%-0.11-4.1%0.093.3%
Usd Price Per Share1.58-1.89-4.45-11.22-17.38-
Price to Earnings Ratio-1.62--2.40--3.13--7.65--12.20-
Price-to-Total Gains Ratio-5.55--11.13--11.57--24.42-595.03-
Price to Book Ratio1.49-1.32-1.58-2.67-3.94-
Price-to-Total Gains Ratio-5.55--11.13--11.57--24.42-595.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.67
Number of shares374
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.17
Usd Book Value Change Per Share-0.24-0.28
Usd Total Gains Per Share-0.24-0.11
Gains per Quarter (374 shares)-90.55-40.47
Gains per Year (374 shares)-362.21-161.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-362-372250-412-172
20-724-734500-824-334
30-1087-1096750-1236-496
40-1449-14581000-1648-658
50-1811-18201251-2060-820
60-2173-21821501-2472-982
70-2535-25441751-2884-1144
80-2898-29062001-3296-1306
90-3260-32682251-3708-1468
100-3622-36302501-4120-1630

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%5.032.00.013.5%5.033.00.013.2%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%2.018.00.010.0%10.027.00.027.0%11.027.00.028.9%
Dividend per Share0.00.04.00.0%2.00.010.016.7%4.00.016.020.0%5.00.032.013.5%5.00.033.013.2%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%11.026.00.029.7%12.026.00.031.6%

Fundamentals of Cellectis

About Cellectis SA

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Fundamental data was last updated by Penke on 2024-03-20 13:35:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Cellectis SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cellectis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cellectis to the Biotechnology industry mean.
  • A Net Profit Margin of -11,278.7% means that $-112.79 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cellectis SA:

  • The MRQ is -11,278.7%. The company is making a huge loss. -2
  • The TTM is -9,764.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-11,278.7%TTM-9,764.3%-1,514.4%
TTM-9,764.3%YOY-3,738.6%-6,025.7%
TTM-9,764.3%5Y-3,225.7%-6,538.6%
5Y-3,225.7%10Y-1,919.1%-1,306.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11,278.7%-171.8%-11,106.9%
TTM-9,764.3%-205.8%-9,558.5%
YOY-3,738.6%-262.1%-3,476.5%
5Y-3,225.7%-455.6%-2,770.1%
10Y-1,919.1%-589.0%-1,330.1%
1.1.2. Return on Assets

Shows how efficient Cellectis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cellectis to the Biotechnology industry mean.
  • -8.3% Return on Assets means that Cellectis generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cellectis SA:

  • The MRQ is -8.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.3%TTM-8.7%+0.4%
TTM-8.7%YOY-8.6%-0.1%
TTM-8.7%5Y-6.6%-2.1%
5Y-6.6%10Y-8.7%+2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.3%-12.5%+4.2%
TTM-8.7%-12.2%+3.5%
YOY-8.6%-11.2%+2.6%
5Y-6.6%-13.4%+6.8%
10Y-8.7%-14.7%+6.0%
1.1.3. Return on Equity

Shows how efficient Cellectis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cellectis to the Biotechnology industry mean.
  • -23.0% Return on Equity means Cellectis generated $-0.23 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cellectis SA:

  • The MRQ is -23.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.0%TTM-20.6%-2.4%
TTM-20.6%YOY-16.1%-4.5%
TTM-20.6%5Y-12.3%-8.2%
5Y-12.3%10Y-30.2%+17.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.0%-15.8%-7.2%
TTM-20.6%-15.7%-4.9%
YOY-16.1%-13.9%-2.2%
5Y-12.3%-18.3%+6.0%
10Y-30.2%-19.2%-11.0%

1.2. Operating Efficiency of Cellectis SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cellectis is operating .

  • Measures how much profit Cellectis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cellectis to the Biotechnology industry mean.
  • An Operating Margin of -13,563.9% means the company generated $-135.64  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cellectis SA:

  • The MRQ is -13,563.9%. The company is operating very inefficient. -2
  • The TTM is -10,941.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-13,563.9%TTM-10,941.5%-2,622.3%
TTM-10,941.5%YOY-5,555.4%-5,386.1%
TTM-10,941.5%5Y-3,918.7%-7,022.8%
5Y-3,918.7%10Y-2,306.3%-1,612.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13,563.9%-299.1%-13,264.8%
TTM-10,941.5%-210.1%-10,731.4%
YOY-5,555.4%-279.7%-5,275.7%
5Y-3,918.7%-459.9%-3,458.8%
10Y-2,306.3%-596.9%-1,709.4%
1.2.2. Operating Ratio

Measures how efficient Cellectis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 134.36 means that the operating costs are $134.36 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cellectis SA:

  • The MRQ is 134.361. The company is inefficient in keeping operating costs low. -1
  • The TTM is 109.798. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ134.361TTM109.798+24.563
TTM109.798YOY51.435+58.363
TTM109.7985Y38.988+70.810
5Y38.98810Y23.667+15.321
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ134.3612.861+131.500
TTM109.7983.193+106.605
YOY51.4353.615+47.820
5Y38.9885.560+33.428
10Y23.6677.396+16.271

1.3. Liquidity of Cellectis SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cellectis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.20 means the company has $2.20 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cellectis SA:

  • The MRQ is 2.195. The company is able to pay all its short-term debts. +1
  • The TTM is 2.361. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.195TTM2.361-0.166
TTM2.361YOY3.528-1.167
TTM2.3615Y5.445-3.084
5Y5.44510Y5.560-0.115
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1953.986-1.791
TTM2.3614.440-2.079
YOY3.5285.552-2.024
5Y5.4456.158-0.713
10Y5.5606.492-0.932
1.3.2. Quick Ratio

Measures if Cellectis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cellectis to the Biotechnology industry mean.
  • A Quick Ratio of 2.03 means the company can pay off $2.03 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cellectis SA:

  • The MRQ is 2.032. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.095. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.032TTM2.095-0.063
TTM2.095YOY3.375-1.280
TTM2.0955Y5.365-3.269
5Y5.36510Y5.614-0.250
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0323.638-1.606
TTM2.0954.168-2.073
YOY3.3755.515-2.140
5Y5.3656.012-0.647
10Y5.6146.209-0.595

1.4. Solvency of Cellectis SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cellectis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cellectis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.64 means that Cellectis assets are financed with 63.7% credit (debt) and the remaining percentage (100% - 63.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cellectis SA:

  • The MRQ is 0.637. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.563. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.637TTM0.563+0.074
TTM0.563YOY0.428+0.135
TTM0.5635Y0.353+0.210
5Y0.35310Y0.320+0.033
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6370.335+0.302
TTM0.5630.330+0.233
YOY0.4280.267+0.161
5Y0.3530.367-0.014
10Y0.3200.378-0.058
1.4.2. Debt to Equity Ratio

Measures if Cellectis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cellectis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 175.5% means that company has $1.75 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cellectis SA:

  • The MRQ is 1.755. The company is just able to pay all its debts with equity.
  • The TTM is 1.353. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.755TTM1.353+0.402
TTM1.353YOY0.806+0.547
TTM1.3535Y0.675+0.677
5Y0.67510Y0.661+0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7550.376+1.379
TTM1.3530.398+0.955
YOY0.8060.334+0.472
5Y0.6750.429+0.246
10Y0.6610.476+0.185

2. Market Valuation of Cellectis SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cellectis generates.

  • Above 15 is considered overpriced but always compare Cellectis to the Biotechnology industry mean.
  • A PE ratio of -1.62 means the investor is paying $-1.62 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cellectis SA:

  • The EOD is -2.740. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.621. Based on the earnings, the company is expensive. -2
  • The TTM is -2.398. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.740MRQ-1.621-1.118
MRQ-1.621TTM-2.398+0.777
TTM-2.398YOY-3.125+0.727
TTM-2.3985Y-7.654+5.256
5Y-7.65410Y-12.203+4.549
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.740-2.643-0.097
MRQ-1.621-2.418+0.797
TTM-2.398-2.742+0.344
YOY-3.125-4.123+0.998
5Y-7.654-6.257-1.397
10Y-12.203-6.478-5.725
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Cellectis SA:

  • The EOD is -2.751. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.628. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 4.448. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-2.751MRQ-1.628-1.123
MRQ-1.628TTM4.448-6.077
TTM4.448YOY-3.112+7.560
TTM4.4485Y-8.916+13.364
5Y-8.91610Y-19.360+10.444
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.751-3.244+0.493
MRQ-1.628-2.939+1.311
TTM4.448-3.478+7.926
YOY-3.112-5.592+2.480
5Y-8.916-8.473-0.443
10Y-19.360-8.881-10.479
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cellectis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.49 means the investor is paying $1.49 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cellectis SA:

  • The EOD is 2.517. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.489. Based on the equity, the company is underpriced. +1
  • The TTM is 1.324. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.517MRQ1.489+1.027
MRQ1.489TTM1.324+0.165
TTM1.324YOY1.580-0.256
TTM1.3245Y2.673-1.348
5Y2.67310Y3.942-1.269
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.5172.124+0.393
MRQ1.4892.041-0.552
TTM1.3242.118-0.794
YOY1.5802.915-1.335
5Y2.6733.682-1.009
10Y3.9424.114-0.172
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cellectis SA.

3.1. Institutions holding Cellectis SA

Institutions are holding 18.806% of the shares of Cellectis SA.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Long Focus Capital Management, LLC6.2540.4594448729300
2023-12-31Capital Research & Mgmt Co - Division 32.57670.0013184880400
2023-12-31Credit Suisse First Boston (CSFB)2.00450.0043143825500
2023-12-31Baillie Gifford & Co Limited.1.13820.002816643-347366-29.8422
2023-12-31Principal Financial Group Inc0.5570.0008399627-256973-39.1369
2023-12-31Macquarie Group Ltd0.31620.000822687500
2023-12-31Kbc Group NV0.22780.001816344700
2023-12-31Oppenheimer & Co Inc0.18560.0075133143117239.6549
2023-12-31Morgan Stanley - Brokerage Accounts0.1062076225863312.7722
2023-12-31LPL Financial Corp0.10060.000172187853013.3999
2023-12-31Two Sigma Investments LLC0.07280.000452247522470
2023-09-30D. E. Shaw & Co LP0.06570.000147154-31675-40.1819
2023-09-30Citadel Advisors Llc0.0478034300431714.3982
2023-12-31Susquehanna International Group, LLP0.0272019524195240
2023-12-31BNP Paribas Arbitrage, SA0.0220.000115800485644.3713
2023-12-31Wells Fargo & Co0.0199014294-1250-8.0417
2023-12-31Geode Capital Management, LLC0.01501077600
2023-12-31Advisor Group Holdings, Inc.0.006404580-4390-48.9409
2023-12-31Qube Research & Technologies0.006204477443711092.5
2023-12-31Rhumbline Advisers0.00540385588529.798
Total 13.75520.47869869506-526502-5.3%

3.2. Funds holding Cellectis SA

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31American Funds SMALLCAP World A2.57670.0079184880400
2024-01-31CS (Lux) Digital Health Equity SB USD2.00450.2856143825500
2024-01-31Principal SmallCap R50.48180.0824345733249007.761
2023-12-31Principal U.S. Small Cap Equity0.44710.0816320833-207367-39.2592
2024-01-31Delaware Healthcare I0.31620.092622687500
2023-08-31Galileo - Biotech Innovation Fund S USD0.28721.341620607100
2024-01-31Baillie Gifford Global Discovery A Acc0.2140.058915352619341.2758
2023-10-31Old Westbury Small & Mid Cap Strategies0.20380.002114620500
2023-12-31Vanguard International Explorer Inv0.17010.0253122028-32610-21.088
2023-12-31JNL Multi-Manager Intl Sm Cp I0.16270.0524116754-17137-12.7992
2023-11-30Edinburgh Worldwide Ord0.11870.0283851945180.6117
2024-01-31Baillie Gifford WW Discovery B USD Acc0.09040.0675648496941.0818
2024-02-29Desjardins SocieTerra Intl Sm Cap Eq F0.06670.18294785900
2024-01-31Principal VC SmallCap 10.06380.08054577900
2024-01-31Principal SmallCap SP0.0460.01593301500
2023-12-31P & S Renditefonds T0.04180.29433000000
2024-01-31Mercer Global Small Cap Equity M-3£0.03440.00922471000
2024-02-29ActivePassive International Equity ETF0.02940.0207211182161.0334
2024-01-31Fidelity Nasdaq Composite Index0.0150.00021077600
2024-01-31Baillie Gifford Intl Smaller Companies0.01450.21761040300
Total 7.38482.94755298787-228852-4.3%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cellectis SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.285-0.242-15%-0.406+43%-0.275-3%-0.002-99%
Book Value Per Share--1.0611.460-27%2.668-60%3.773-72%3.697-71%
Current Ratio--2.1952.361-7%3.528-38%5.445-60%5.560-61%
Debt To Asset Ratio--0.6370.563+13%0.428+49%0.353+80%0.320+99%
Debt To Equity Ratio--1.7551.353+30%0.806+118%0.675+160%0.661+166%
Dividend Per Share----0%0.003-100%0.167-100%0.091-100%
Eps---0.244-0.229-6%-0.363+49%-0.325+33%-0.299+23%
Free Cash Flow Per Share---0.243-0.222-9%-0.387+60%-0.355+46%-0.237-2%
Free Cash Flow To Equity Per Share---0.219-0.095-57%-0.370+69%-0.276+26%0.022-1112%
Gross Profit Margin--1.0001.192-16%1.052-5%1.092-8%1.094-9%
Intrinsic Value_10Y_max---1.821--------
Intrinsic Value_10Y_min---2.070--------
Intrinsic Value_1Y_max---1.336--------
Intrinsic Value_1Y_min---1.313--------
Intrinsic Value_3Y_max---3.135--------
Intrinsic Value_3Y_min---3.011--------
Intrinsic Value_5Y_max---3.875--------
Intrinsic Value_5Y_min---3.672--------
Market Cap191575704.000+41%113366896.000135923679.500-17%318934084.000-64%804752490.300-86%1246778909.135-91%
Net Profit Margin---112.787-97.643-13%-37.386-67%-32.257-71%-19.191-83%
Operating Margin---135.639-109.415-19%-55.554-59%-39.187-71%-23.063-83%
Operating Ratio--134.361109.798+22%51.435+161%38.988+245%23.667+468%
Pb Ratio2.517+41%1.4891.324+12%1.580-6%2.673-44%3.942-62%
Pe Ratio-2.740-69%-1.621-2.398+48%-3.125+93%-7.654+372%-12.203+653%
Price Per Share2.670+41%1.5801.894-17%4.445-64%11.216-86%17.376-91%
Price To Free Cash Flow Ratio-2.751-69%-1.6284.448-137%-3.112+91%-8.916+448%-19.360+1089%
Price To Total Gains Ratio-9.375-69%-5.548-11.127+101%-11.573+109%-24.417+340%595.034-101%
Quick Ratio--2.0322.095-3%3.375-40%5.365-62%5.614-64%
Return On Assets---0.083-0.087+4%-0.086+4%-0.066-20%-0.087+5%
Return On Equity---0.230-0.206-10%-0.161-30%-0.123-46%-0.302+31%
Total Gains Per Share---0.285-0.242-15%-0.403+41%-0.108-62%0.088-422%
Usd Book Value--76123000.000104777750.000-27%191415250.000-60%270730700.000-72%265232556.758-71%
Usd Book Value Change Per Share---0.285-0.242-15%-0.406+43%-0.275-3%-0.002-99%
Usd Book Value Per Share--1.0611.460-27%2.668-60%3.773-72%3.697-71%
Usd Dividend Per Share----0%0.003-100%0.167-100%0.091-100%
Usd Eps---0.244-0.229-6%-0.363+49%-0.325+33%-0.299+23%
Usd Free Cash Flow---17408000.000-15895750.000-9%-27773500.000+60%-25449300.000+46%-16992461.261-2%
Usd Free Cash Flow Per Share---0.243-0.222-9%-0.387+60%-0.355+46%-0.237-2%
Usd Free Cash Flow To Equity Per Share---0.219-0.095-57%-0.370+69%-0.276+26%0.022-1112%
Usd Market Cap191575704.000+41%113366896.000135923679.500-17%318934084.000-64%804752490.300-86%1246778909.135-91%
Usd Price Per Share2.670+41%1.5801.894-17%4.445-64%11.216-86%17.376-91%
Usd Profit---17482000.000-20976500.000+20%-29035000.000+66%-24865550.000+42%-21347891.545+22%
Usd Revenue--155000.0004124000.000-96%4227750.000-96%8371050.000-98%8872412.593-98%
Usd Total Gains Per Share---0.285-0.242-15%-0.403+41%-0.108-62%0.088-422%
 EOD+5 -3MRQTTM+5 -29YOY+16 -205Y+11 -2510Y+7 -29

4.2. Fundamental Score

Let's check the fundamental score of Cellectis SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.740
Price to Book Ratio (EOD)Between0-12.517
Net Profit Margin (MRQ)Greater than0-112.787
Operating Margin (MRQ)Greater than0-135.639
Quick Ratio (MRQ)Greater than12.032
Current Ratio (MRQ)Greater than12.195
Debt to Asset Ratio (MRQ)Less than10.637
Debt to Equity Ratio (MRQ)Less than11.755
Return on Equity (MRQ)Greater than0.15-0.230
Return on Assets (MRQ)Greater than0.05-0.083
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Cellectis SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.235
Ma 20Greater thanMa 502.541
Ma 50Greater thanMa 1002.733
Ma 100Greater thanMa 2002.848
OpenGreater thanClose2.560
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets209,700
Total Liabilities133,577
Total Stockholder Equity76,123
 As reported
Total Liabilities 133,577
Total Stockholder Equity+ 76,123
Total Assets = 209,700

Assets

Total Assets209,700
Total Current Assets96,495
Long-term Assets113,205
Total Current Assets
Cash And Cash Equivalents 67,358
Net Receivables 21,973
Inventory 6,906
Other Current Assets 258
Total Current Assets  (as reported)96,495
Total Current Assets  (calculated)96,495
+/-0
Long-term Assets
Property Plant Equipment 95,919
Long Term Investments 11,184
Intangible Assets 662
Long-term Assets Other 4,656
Long-term Assets  (as reported)113,205
Long-term Assets  (calculated)112,421
+/- 784

Liabilities & Shareholders' Equity

Total Current Liabilities43,954
Long-term Liabilities89,623
Total Stockholder Equity76,123
Total Current Liabilities
Short-term Debt 13,137
Short Long Term Debt 4,934
Accounts payable 20,476
Other Current Liabilities 10,224
Total Current Liabilities  (as reported)43,954
Total Current Liabilities  (calculated)48,771
+/- 4,817
Long-term Liabilities
Long term Debt 26,997
Capital Lease Obligations 52,019
Long-term Liabilities Other 12,426
Long-term Liabilities  (as reported)89,623
Long-term Liabilities  (calculated)91,442
+/- 1,819
Total Stockholder Equity
Common Stock3,492
Retained Earnings -363,191
Accumulated Other Comprehensive Income -37,505
Other Stockholders Equity 473,327
Total Stockholder Equity (as reported)76,123
Total Stockholder Equity (calculated)76,123
+/-0
Other
Capital Stock3,492
Cash and Short Term Investments 67,358
Common Stock Shares Outstanding 55,584
Current Deferred Revenue117
Liabilities and Stockholders Equity 209,700
Net Debt 16,592
Net Invested Capital 108,054
Net Working Capital 52,541
Property Plant and Equipment Gross 164,662
Short Long Term Debt Total 83,950



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-06-302013-12-312013-06-302012-12-312012-06-302011-12-312010-12-312010-06-302009-12-312009-06-302008-12-31
> Total Assets 
60,832
58,934
91,339
72,336
69,231
131,886
117,351
115,106
90,933
44,113
58,594
167,340
367,939
344,650
339,956
372,884
356,593
358,602
352,469
330,678
325,847
328,639
349,395
332,882
324,048
534,066
519,799
500,840
511,938
505,323
480,475
467,469
471,135
472,696
484,957
469,471
442,712
457,565
412,886
382,076
347,191
320,883
279,580
261,216
251,408
227,674
209,700
209,700227,674251,408261,216279,580320,883347,191382,076412,886457,565442,712469,471484,957472,696471,135467,469480,475505,323511,938500,840519,799534,066324,048332,882349,395328,639325,847330,678352,469358,602356,593372,884339,956344,650367,939167,34058,59444,11390,933115,106117,351131,88669,23172,33691,33958,93460,832
   > Total Current Assets 
48,143
44,447
74,758
54,937
47,567
70,627
54,362
51,467
31,015
27,541
50,146
160,515
359,005
337,074
332,832
365,401
341,136
339,455
333,471
311,786
306,306
308,602
338,707
323,222
313,958
524,576
509,491
487,641
459,555
439,163
410,734
391,520
377,931
347,927
345,718
315,362
272,387
280,352
235,849
225,429
195,175
175,167
140,272
143,811
137,365
113,284
96,495
96,495113,284137,365143,811140,272175,167195,175225,429235,849280,352272,387315,362345,718347,927377,931391,520410,734439,163459,555487,641509,491524,576313,958323,222338,707308,602306,306311,786333,471339,455341,136365,401332,832337,074359,005160,51550,14627,54131,01551,46754,36270,62747,56754,93774,75844,44748,143
       Cash And Cash Equivalents 
39,781
37,983
65,326
46,509
31,983
54,934
35,240
28,841
12,415
10,438
27,578
136,615
128,204
318,415
314,332
343,557
215,777
202,440
209,010
290,497
237,200
231,827
263,862
296,982
241,363
471,215
475,775
451,889
421,457
396,967
342,485
360,907
287,133
260,710
260,941
268,239
207,457
248,226
210,709
186,135
154,868
129,440
119,008
97,697
83,515
85,505
67,358
67,35885,50583,51597,697119,008129,440154,868186,135210,709248,226207,457268,239260,941260,710287,133360,907342,485396,967421,457451,889475,775471,215241,363296,982263,862231,827237,200290,497209,010202,440215,777343,557314,332318,415128,204136,61527,57810,43812,41528,84135,24054,93431,98346,50965,32637,98339,781
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
787
0
0
0
0
97,602
97,578
87,131
36,509
39,066
39,990
40,240
40,602
40,700
19,872
139
388
382
389
20,381
20,385
59,005
50,378
41,242
27,091
18,438
3,393
393
499
0
0
21,359
7,907
4,647
1,120
0
01,1204,6477,90721,359004993933,39318,43827,09141,24250,37859,00520,38520,38138938238813919,87240,70040,60240,24039,99039,06636,50987,13197,57897,602000078700000000000
       Net Receivables 
5,030
3,610
2,523
6,972
12,075
10,984
18,281
21,689
18,107
16,134
17,295
19,641
0
10,497
10,203
16,549
20,714
31,272
29,623
12,323
19,536
22,624
21,896
12,277
17,927
19,651
19,222
20,144
24,102
27,723
31,515
12,099
17,866
12,825
12,400
15,874
21,427
11,948
10,231
29,629
33,760
15,532
12,954
15,268
21,870
19,910
21,973
21,97319,91021,87015,26812,95415,53233,76029,62910,23111,94821,42715,87412,40012,82517,86612,09931,51527,72324,10220,14419,22219,65117,92712,27721,89622,62419,53612,32329,62331,27220,71416,54910,20310,497019,64117,29516,13418,10721,68918,28110,98412,0756,9722,5233,6105,030
       Inventory 
168
170
169
172
203
811
841
935
493
507
377
164
0
200
200
173
117
139
119
118
113
130
125
250
203
231
223
275
1,054
986
3,344
2,897
3,591
5,710
6,262
1,606
5,315
2,468
1,674
0
6,548
30,194
-21,159
21,768
26,960
0
6,906
6,906026,96021,768-21,15930,1946,54801,6742,4685,3151,6066,2625,7103,5912,8973,3449861,0542752232312032501251301131181191391171732002000164377507493935841811203172169170168
       Other Current Assets 
3,164
2,684
2,324
1,284
3,306
3,897
0
1
-1
463
352
1,781
359,005
7,962
8,097
5,122
811
775
740
8,849
694
2,902
1,263
13,713
1
-2
-1
15,333
1
16,496
15,321
15,617
1
21,786
24,873
29,643
-1
1
439
9,665
-1
1
8,310
9,078
373
7,869
258
2587,8693739,0788,3101-19,6654391-129,64324,87321,786115,61715,32116,496115,333-1-2113,7131,2632,9026948,8497407758115,1228,0977,962359,0051,781352463-1103,8973,3061,2842,3242,6843,164
   > Long-term Assets 
12,689
14,487
16,581
17,399
21,664
61,260
62,989
63,638
59,920
16,572
8,448
6,825
8,934
7,576
7,125
7,483
15,456
19,147
18,997
18,892
19,541
20,036
10,688
9,661
10,090
9,490
10,308
13,199
52,382
66,161
69,740
75,949
93,204
124,769
139,239
154,109
170,325
177,214
177,037
156,647
152,016
145,716
139,307
117,406
114,042
114,389
113,205
113,205114,389114,042117,406139,307145,716152,016156,647177,037177,214170,325154,109139,239124,76993,20475,94969,74066,16152,38213,19910,3089,49010,0909,66110,68820,03619,54118,89218,99719,14715,4567,4837,1257,5768,9346,8258,44816,57259,92063,63862,98961,26021,66417,39916,58114,48712,689
       Property Plant Equipment 
1,988
1,223
1,272
1,214
5,204
8,579
7,409
7,253
6,587
5,343
3,924
3,173
0
5,747
5,495
5,514
13,210
16,903
16,986
16,862
17,171
17,691
8,227
7,226
7,689
7,435
8,300
10,041
46,476
60,195
63,151
69,324
84,625
116,323
128,384
145,518
146,615
153,528
152,440
148,269
143,752
135,039
128,871
107,896
105,143
100,688
95,919
95,919100,688105,143107,896128,871135,039143,752148,269152,440153,528146,615145,518128,384116,32384,62569,32463,15160,19546,47610,0418,3007,4357,6897,2268,22717,69117,17116,86216,98616,90313,2105,5145,4955,74703,1733,9245,3436,5877,2537,4098,5795,2041,2141,2721,2231,988
       Goodwill 
0
0
0
0
0
0
0
37,916
0
1,512
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
1
0
0
0
0
0
0
0
00000001000-100000000000000000000000001,512037,9160000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
435
0
177
0
0
0
701
0
0
0
356
886
953
989
0
897
0
0
0
4,684
4,755
5,468
5,517
7,484
7,376
9,781
7,007
22,105
22,101
22,045
6,524
6,567
9,093
8,926
8,791
8,185
13,006
11,184
11,18413,0068,1858,7918,9269,0936,5676,52422,04522,10122,1057,0079,7817,3767,4845,5175,4684,7554,68400089709899538863560007010001770435000000000
       Intangible Assets 
0
0
23
0
5,288
45,625
0
50,019
48,880
7,631
3,790
1,249
0
1,083
1,075
1,045
1,316
1,399
1,326
1,340
1,425
1,384
1,470
1,431
1,505
1,386
1,352
1,268
1,222
1,209
1,120
1,108
1,094
1,071
1,074
1,585
1,604
0
0
1,853
0
0
1,511
718
0
695
662
66269507181,511001,853001,6041,5851,0741,0711,0941,1081,1201,2091,2221,2681,3521,3861,5051,4311,4701,3841,4251,3401,3261,3991,3161,0451,0751,08301,2493,7907,63148,88050,019045,6255,28802300
       Long-term Assets Other 
1
15
0
12
0
1
46,265
0
1
1
0
0
0
1
1
1
0
1,410
1,324
0
0
2
2
102
-1
2
-1
-1
52,382
2
1
5,517
1
-1
0
-1
1
1
1
3
-1
0
-1
1
1
800
4,656
4,65680011-10-13111-10-115,5171252,382-1-12-110222001,3241,410011100011046,26510120151
> Total Liabilities 
14,621
15,840
18,119
12,637
19,104
94,865
26,813
33,420
34,702
37,463
31,376
94,955
367,939
71,854
70,390
84,669
77,871
73,817
66,316
56,632
54,491
57,197
49,257
46,978
47,310
45,292
48,479
50,569
79,632
100,215
98,704
111,999
100,548
127,637
158,747
160,625
152,968
155,242
150,739
145,602
144,137
140,362
133,968
135,275
130,919
131,116
133,577
133,577131,116130,919135,275133,968140,362144,137145,602150,739155,242152,968160,625158,747127,637100,548111,99998,704100,21579,63250,56948,47945,29247,31046,97849,25757,19754,49156,63266,31673,81777,87184,66970,39071,854367,93994,95531,37637,46334,70233,42026,81394,86519,10412,63718,11915,84014,621
   > Total Current Liabilities 
12,781
14,233
15,442
10,787
17,020
26,959
22,359
28,356
29,585
32,201
26,960
91,037
84,880
71,312
69,886
84,119
77,295
73,147
65,621
56,043
53,880
56,524
48,543
43,534
43,736
42,008
45,362
46,869
47,054
51,821
51,381
62,604
49,008
53,052
56,613
52,015
46,922
51,446
49,603
49,348
52,337
55,282
53,030
62,995
60,468
42,047
43,954
43,95442,04760,46862,99553,03055,28252,33749,34849,60351,44646,92252,01556,61353,05249,00862,60451,38151,82147,05446,86945,36242,00843,73643,53448,54356,52453,88056,04365,62173,14777,29584,11969,88671,31284,88091,03726,96032,20129,58528,35622,35926,95917,02010,78715,44214,23312,781
       Short-term Debt 
0
0
0
0
745
1,572
1,588
1,307
1,265
954
1,684
1,048
0
3,401
3,354
2,100
2,149
2,417
2,156
1,726
405
70
29
21
82
772
277
333
5,385
2,104
2,996
1,067
1,342
3,777
4,331
6,696
6,985
7,691
8,079
10,683
11,893
12,932
18,350
12,960
13,249
13,455
13,137
13,13713,45513,24912,96018,35012,93211,89310,6838,0797,6916,9856,6964,3313,7771,3421,0672,9962,1045,385333277772822129704051,7262,1562,4172,1492,1003,3543,40101,0481,6849541,2651,3071,5881,5727450000
       Short Long Term Debt 
0
0
0
0
0
0
0
1,316
0
4,066
0
596
0
0
0
1,997
0
0
0
68
55
54
44
34
347
1,003
0
0
5,385
2,104
2,996
1,067
1,342
0
4,331
0
0
0
0
2,246
3,485
4,841
10,379
5,088
5,068
5,185
4,934
4,9345,1855,0685,08810,3794,8413,4852,24600004,33101,3421,0672,9962,1045,385001,00334734445455680001,99700059604,06601,3160000000
       Accounts payable 
0
6,429
6,778
5,989
11,257
25,387
20,771
27,048
28,321
12,977
11,954
11,919
0
5,998
7,499
7,228
8,967
12,596
10,294
9,700
13,005
17,205
12,693
9,460
11,254
12,734
15,597
15,883
15,698
19,760
19,761
29,264
26,873
32,674
35,003
24,609
24,682
28,254
22,809
23,762
20,921
24,159
22,353
21,456
22,324
19,229
20,476
20,47619,22922,32421,45622,35324,15920,92123,76222,80928,25424,68224,60935,00332,67426,87329,26419,76119,76015,69815,88315,59712,73411,2549,46012,69317,20513,0059,70010,29412,5968,9677,2287,4995,998011,91911,95412,97728,32127,04820,77125,38711,2575,9896,7786,4290
       Other Current Liabilities 
12,781
7,805
8,664
4,798
342
0
0
1
-1
10,519
6,199
5,726
0
6,425
9,704
14,924
9,323
8,502
6,171
5,777
5,089
6,527
6,058
7,997
7,296
8,102
9,236
9,899
5,691
9,572
9,038
12,240
20,250
16,118
16,839
20,258
14,991
15,078
18,215
14,602
18,942
17,791
12,007
28,520
24,553
9,122
10,224
10,2249,12224,55328,52012,00717,79118,94214,60218,21515,07814,99120,25816,83916,11820,25012,2409,0389,5725,6919,8999,2368,1027,2967,9976,0586,5275,0895,7776,1718,5029,32314,9249,7046,42505,7266,19910,519-11003424,7988,6647,80512,781
   > Long-term Liabilities 
1,840
1,606
2,676
1,850
2,084
67,906
4,454
5,064
5,117
5,263
4,416
3,918
572
543
504
550
576
670
694
589
611
673
714
3,444
3,574
3,284
3,117
3,700
32,578
48,394
47,323
49,395
51,540
74,585
102,134
108,610
106,046
103,796
101,136
96,254
91,800
85,080
80,938
72,280
70,451
89,069
89,623
89,62389,06970,45172,28080,93885,08091,80096,254101,136103,796106,046108,610102,13474,58551,54049,39547,32348,39432,5783,7003,1173,2843,5743,4447146736115896946705765505045435723,9184,4165,2635,1175,0644,45467,9062,0841,8502,6761,6061,840
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,018
30,263
45,710
44,466
46,540
48,699
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000048,69946,54044,46645,71030,2631,018000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
1,035
0
602
0
482
0
437
417
474
516
623
654
561
590
650
697
3,431
3,309
3,053
2,908
2,682
2,315
2,684
2,857
2,855
2,841
9,721
34,777
8,627
7,927
4,597
5,927
5,957
4,947
4,056
3,821
9,353
0
14,944
0
014,94409,3533,8214,0564,9475,9575,9274,5977,9278,62734,7779,7212,8412,8552,8572,6842,3152,6822,9083,0533,3093,4316976505905616546235164744174370482060201,0350000000
> Total Stockholder Equity
46,211
43,094
73,221
59,699
50,128
37,022
87,634
78,927
53,889
6,949
28,126
73,917
283,592
272,613
269,271
287,423
277,782
283,489
284,503
272,175
269,236
267,875
282,405
266,791
255,324
447,728
430,648
409,301
391,150
363,824
340,636
315,123
331,843
307,606
290,369
275,573
261,926
275,865
237,967
221,293
191,044
168,933
136,641
117,968
113,735
96,558
76,123
76,12396,558113,735117,968136,641168,933191,044221,293237,967275,865261,926275,573290,369307,606331,843315,123340,636363,824391,150409,301430,648447,728255,324266,791282,405267,875269,236272,175284,503283,489277,782287,423269,271272,613283,59273,91728,1266,94953,88978,92787,63437,02250,12859,69973,22143,09446,211
   Common Stock
46,211
672
834
710
777
104,202
167,093
174,551
171,715
1,455
1,711
1,790
0
1,966
1,975
1,923
1,996
1,965
1,982
1,858
1,888
2,051
2,365
2,367
2,374
2,764
2,765
2,765
2,765
2,766
2,766
2,767
2,767
2,768
2,768
2,785
2,801
2,947
2,946
2,945
2,945
2,946
2,949
2,955
3,487
3,491
3,492
3,4923,4913,4872,9552,9492,9462,9452,9452,9462,9472,8012,7852,7682,7682,7672,7672,7662,7662,7652,7652,7652,7642,3742,3672,3652,0511,8881,8581,9821,9651,9961,9231,9751,96601,7901,7111,455171,715174,551167,093104,20277771083467246,211
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
-2,424
-2,608
-5,519
-4,255
0
0
0
-66,719
-95,015
-94,220
-175,722
-162,092
0
-1,672
-2,390
-1,783
-3,996
-1,680
-2,169
2,630
1,520
-3,466
-530
1,978
6,097
-11,534
-13,561
-16,668
-22,385
-18,903
-30,518
-22,640
-29,254
-23,730
-13,556
-4,089
-12,363
-9,602
-14,345
-18,021
-21,261
-29,626
-35,434
-28,605
-28,542
-37,050
-37,505
-37,505-37,050-28,542-28,605-35,434-29,626-21,261-18,021-14,345-9,602-12,363-4,089-13,556-23,730-29,254-22,640-30,518-18,903-22,385-16,668-13,561-11,5346,0971,978-530-3,4661,5202,630-2,169-1,680-3,996-1,783-2,390-1,6720-162,092-175,722-94,220-95,015-66,719000-4,255-5,519-2,608-2,424
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
828,525
831,282
834,830
839,437
843,478
846,839
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000846,839843,478839,437834,830831,282828,525000000000000000000000000000
   Treasury Stock000000000000000000000-587-373-297-302-227-170-324-419-264-216-200-380-2110-3040-568000000000
   Other Stockholders Equity 
2,424
48,913
77,906
63,244
60,074
1
-1
0
-1
183,992
208,319
234,194
0
444,103
456,385
459,731
491,933
498,492
516,180
497,453
519,167
568,029
604,249
613,741
625,260
815,776
823,353
828,525
831,282
834,830
839,438
843,478
846,839
849,322
851,348
863,912
869,695
920,591
925,290
934,695
937,333
567,283
579,047
583,122
608,084
476,224
473,327
473,327476,224608,084583,122579,047567,283937,333934,695925,290920,591869,695863,912851,348849,322846,839843,478839,438834,830831,282828,525823,353815,776625,260613,741604,249568,029519,167497,453516,180498,492491,933459,731456,385444,1030234,194208,319183,992-10-1160,07463,24477,90648,9132,424



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue16,496
Cost of Revenue-1,261
Gross Profit15,23515,235
 
Operating Income (+$)
Gross Profit15,235
Operating Expense-89,993
Operating Income-73,497-74,758
 
Operating Expense (+$)
Research Development83,553
Selling General Administrative9,514
Selling And Marketing Expenses-
Operating Expense89,99393,067
 
Net Interest Income (+$)
Interest Income2,609
Interest Expense-4,695
Other Finance Cost-8,355
Net Interest Income6,269
 
Pretax Income (+$)
Operating Income-73,497
Net Interest Income6,269
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-78,575-62,150
EBIT - interestExpense = -4,695
-85,010
-80,315
Interest Expense4,695
Earnings Before Interest and Taxes (EBIT)--73,880
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-78,575
Tax Provision-452
Net Income From Continuing Ops-79,026-79,027
Net Income-85,010
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-11,347-6,269
 

Technical Analysis of Cellectis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Cellectis. The general trend of Cellectis is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Cellectis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Cellectis SA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.78 < 2.95 < 3.13.

The bearish price targets are: 2.3501 > 2.1497 > 1.75.

Tweet this
Cellectis SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Cellectis SA. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Cellectis SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Cellectis SA. The current macd is -0.05037001.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellectis price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Cellectis. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Cellectis price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Cellectis SA Daily Moving Average Convergence/Divergence (MACD) ChartCellectis SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Cellectis SA. The current adx is 20.52.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Cellectis shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Cellectis SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Cellectis SA. The current sar is 2.3501.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Cellectis SA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Cellectis SA. The current rsi is 53.23. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Cellectis SA Daily Relative Strength Index (RSI) ChartCellectis SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Cellectis SA. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Cellectis price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Cellectis SA Daily Stochastic Oscillator ChartCellectis SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Cellectis SA. The current cci is 124.59.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Cellectis SA Daily Commodity Channel Index (CCI) ChartCellectis SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Cellectis SA. The current cmo is 19.15.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Cellectis SA Daily Chande Momentum Oscillator (CMO) ChartCellectis SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Cellectis SA. The current willr is -25.58734589.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Cellectis is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Cellectis SA Daily Williams %R ChartCellectis SA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Cellectis SA.

Cellectis SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Cellectis SA. The current atr is 0.16044445.

Cellectis SA Daily Average True Range (ATR) ChartCellectis SA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Cellectis SA. The current obv is 95,703,850.

Cellectis SA Daily On-Balance Volume (OBV) ChartCellectis SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Cellectis SA. The current mfi is 48.24.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Cellectis SA Daily Money Flow Index (MFI) ChartCellectis SA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Cellectis SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Cellectis SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Cellectis SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.235
Ma 20Greater thanMa 502.541
Ma 50Greater thanMa 1002.733
Ma 100Greater thanMa 2002.848
OpenGreater thanClose2.560
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Cellectis with someone you think should read this too:
  • Are you bullish or bearish on Cellectis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Cellectis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Cellectis SA

I send you an email if I find something interesting about Cellectis SA.


Comments

How you think about this?

Leave a comment

Stay informed about Cellectis SA.

Receive notifications about Cellectis SA in your mailbox!